<a href="https://www.fiercebiotech.com/biotech/has-novartis-t-charge-been-overtaken-vivo-car-ts-execs-argue-theres-room-both" hreflang="en">Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both</a>
Novartis' T-Charge CAR-T platform, which aims to enhance T cell efficacy by reducing ex vivo processing time, faces competition from emerging in vivo CAR-T therapies that generate cells within the patient. Despite the growing interest in in vivo options and recent acquisitions by other pharma companies, Novartis remains optimistic about the potential of both platforms and continues to develop its T-Charge candidate, rap-cel, for various blood cancers and autoimmune diseases.
For a professional tracking healthtech and biotech sectors, particularly in CAR-T innovations, the key insight is that while in vivo CAR-T therapies are gaining traction due to their potential to simplify the manufacturing process and broaden accessibility, Novartis is strategically maintaining a dual focus. They continue to advance their T-Charge platform for durable efficacy outcomes and are cautiously exploring in vivo opportunities. This suggests a balanced investment in both cutting-edge and established CAR-T methodologies, highlighting potential areas for partnership or innovation in the evolving cell therapy landscape.